Abbott says ID NOW COVID-19 rapid test shows high sensitivity in study
(Reuters) - Abbott Laboratories said on Wednesday its ID NOW COVID-19 rapid test showed 96.2% sensitivity and 99.5% specificity compared to lab-based molecular PCR tests, according to interim data from a study.
The results confirm the data submitted to the U.S. Food and Drug Administration in March for emergency use authorization, the medical device maker said.
OCTOBER 7, 2020
https://www.reuters.com/
